Introduction
More than any other disease prostate cancer seems to produce controversy. At present, screening, radical prostatectomy and maximal androgen blockade are the topics producing the most vigorous arguments. Ten years ago, the major issue was the timing of hormonal treatment. 1 An issue ever since hormone therapy was introduced, 2 opinion has swung ®rst in favour of immediate treatment and then back to deferred treatment. The enthusiasm throughout the 1950s and 1960s for aggressive early hormone treatment was based on publications which did not recognise the pitfalls of historic controls. 2 Later data swung opinion towards deferred treatment. This did come from randomised trials, 3 but ones not designed primarily to answer this speci®c question, and with study populations not typical of the men who we treat for prostate cancer in the 1990s. Because of the importance attached to this question the main activity of the Medical Research Council's Prostate Cancer Working Party in the late 1980s was a trial directed to resolving this issue. 4 The ®rst results from this trial have recently been published. 5 They probably will not be the last word on the subject, but do provide a good opportunity to review this topic.
Hormone therapy for prostate cancer
Androgen deprivation continues to be the main treatment for advanced prostate cancer, especially metastatic disease. 6 While hormone therapy commenced as soon as possible is invariably indicated for metastatic prostate cancer presenting with bone pain or other symptoms, or in locally advanced disease causing ureteric obstruction, in the asymptomatic patient with metastatic or advanced localised disease the possibility of deferring treatment arises. In the Veterans Administration Cooperative Research Group (VACURG) studies, 3 in randomised control groups treated initially with a placebo, but started on active treatment on progression, survival seemed no worse than in those commenced on effective treatment from the outset. As a result, deferred treatment became popular, although Byar 3 in his review in 1973, only stated that`These data support the concept that treatment can be delayed F F F ' recognising that since the VACURG studies were not speci®cally designed to answer this question, they could not provide a de®nitive conclusion, and indeed the same data can be used to argue in favour of immediate treatment. In the VACURG studies, even in those with metastatic disease, only 50% of patients dying did so from prostate cancer and this result has frequently been quoted to suggest that many patients might not need treatment in their life time. While deferring treatment until an indication arises would be preferable unless early treatment can be shown to have advantages 7 a number of arguments could be advanced in favour of early treatment 1. Treatment while tumour bulk is smaller should be more effective. 2. The evidence that deferring treatment has no effect on survival was not conclusive. 3. Prostate cancer may become less hormone sensitive as it progresses. 4. Local progression in the absence of treatment increases the number of patients requiring TURP for recurrent out¯ow obstruction. 5. Catastrophic events such as spinal cord compression and pathological fractures may occur in untreated patients. 6. The absence of speci®c symptoms might mask a general malaise associated with uncontrolled cancerÐthe patient might simply feel better if he were treated.
However, little hard data were available to support these arguments. As new developments such as LH RH analogues were perceived to have fewer disadvantages than older methods of hormone therapy, it was suggested that there was less reason to avoid treatment. 8 It also appeared that any bene®t from maximal androgen blockade appeared most marked in those with least disease, 9 reviving an old argument that as prostate cancer progresses it loses its hormone sensitivity. 2 Thus in the early part of this decade, opinion was once more in favour of immediate treatment.
The Medical Research Council study
Recruitment into the MRC study ended in 1993 with 938 patients entered, and the ®rst results have recently been published. 5 It was designed to assess the impact of hormonal treatment commenced at the time of diagnosis on the course of the disease compared to delaying treatment until clinical progression occurred. Participants were encouraged to manage patients according to their clinical practice. Entry and follow up were simpli®ed as much as possible, and only data considered relevant to the main issue were collected. Eligibility was largely governed by Peto's uncertainty principleÐif the clinician had genuine uncertainty as to whether the patient would bene®t from immediate hormone treatment, and no clear reason to defer treatment, and provided this concurred with the informed view of the patient, he was eligible for entry. Similarly, indications for treatment in deferred patients were at the discretion of the participant. The results were analysed on an intention to treat basis. Thus the trial compares the impact of adopting a policy of immediate treatment rather than deferred treatment upon the outcome of advanced prostate cancer as managed in routine clinical practice in the UK. While the absence of stringent follow-up schedules in the protocol has been criticised, by re¯ecting normal clinical practice in the UK at the time of the trial the results become more applicable to every day urology than those of a trial conducted within an arti®cially rigorous framework. The following brief review of the main ®ndings includes some recent data to May 1997.
Of those randomised to deferred treatment, 50% of patients with metastases (M1) had been treated for nine months after randomisation compared with 27 months in those with non metastatic disease. Approximately 10% died from other causes before treatment was indicated, mostly patients over the age of 70 y and mainly with non metastatic disease at presentation. On the other hand, some 5% died from prostate cancer without receiving treatment. Surprisingly, most of these had M0 disease at randomisation, but the majority were aged over 75 y.
As would be expected, progression from M0 to M1 disease was signi®cantly more rapid in patients with deferred treatment, and in those with M1 disease at randomisation, bone pain occurred earlier. Local progression also was more rapid, and 143 patients in the deferred arm have needed a TURP compared to 72 of those treated immediately, a proportion which was similar in M0 and M1 patients. The incidence of spinal cord compression, pathological fracture, ureteric obstruction, and extra skeletal metastases was more frequent in deferred patients (Table 1) , the patient with metastatic disease being most at risk. Of 23 patients randomised to deferred treatment who developed spinal cord compression in 19 it occurred after hormonal treatment had already been started for another indication. There was a statistically signi®cant improvement in survival in those receiving immediate treatment, both in overall but more markedly in disease speci®c survival (Figure 1 ). In the age group of these patients, prolongation of disease speci®c survival will enable some patients who would have died from their cancer to live long enough to die from another cause. The survival curves for non prostate cancer deaths indicate that about half the patients would have died within seven years if they had not had prostate cancer, and the observed overall survival is probably what would be expected to accrue from the recorded bene®t in disease speci®c survival in this age group (PetoÐpersonal communication). It was mainly in those with M0 disease that overall and prostate cancer survival was signi®cantly improved in the immediate treatment group; in those with metastatic disease, no clear difference in survival can be identi®ed.
Of all patients who died during the study, 67% did so from prostate cancer, a proportion rising to 78% in those with M1 disease on entry. The relevant ®gures in the VACURG studies were 41 and 50% respectively. Clearly, improvements in life expectation now make prostate cancer a more potent cause of death, and reduce the chance of a man avoiding the need for treatment, re¯ected in the fact that few men entered under the age of 70 y died from other causes before treatment was started.
Criticisms of the study
Super®cially the results of this study give little comfort to the supporters of deferred treatment. However, the study has two irrevocable de®ciencies. As the routine use of PSA in monitoring prostate cancer is comparatively recent, the MRC study was not, unfortunately, able to collect information on PSA levels on diagnosis or followup. A high PSA correlates with tumour progression. 10 The use of PSA in assessing and monitoring patients can reduce some of the concern about missing tumour progression in deferred treatment patients. In patients who are keen to avoid treatment, a short period monitoring PSA, with the advice that a rapid rise should be taken as an indication for treatment seems a reasonable compromise.
At the time the study was commenced, there were no validated quality of life questionnaires available, and indeed, the level of recruitment achieved, in a study largely performed by busy district general hospital urologists without signi®cant ®nancial support, might have been jeopardised by such an addition. Thus it is not possible to assess the adverse effects of treatment on those in the immediate arm. In the absence of such quality of life data, the case against deferred treatment will depend on its de®ciencies being so great that they will clearly mitigate any treatment induced loss of quality of life. For those with metastatic disease the majority are not going to escape treatment, usually needed within a matter of months, and although early treatment may have little impact on survival, it is those with metastatic disease at presentation who seem at most risk from the increased incidence of spinal cord compression and pathological fracture. There will be an increased chance that during this relatively short survival, the patient will require a further TURP, as happened to 31 out of 131 (24%) deferred M1 patients, compared to 12 out of 130 (9%) treated immediately. In patients without metastatic disease at presentation, the survival bene®t from immediate treatment alone seems suf®cient to amply justify the imposition of hormonal treatment.
The results of the study also can be debated at another level. Is the outcome a purely clinical effect, or is it a re¯ection of the effect of timing of treatment on the biology of prostate cancer. In practical terms, could the apparently harmful effects of delaying treatment be avoided by a more rigorous follow-up. Certainly, the high workload of most British urologists might inhibit their ability to give patients the attention needed to safely defer treatment. It has been suggested that in other health systems, deferred treatment would be safer and thus bene®cial (WalshÐunpublished observation) and that a trial with a rigorous follow up schedule would have had a different outcome (SchroederÐpersonal communication). Central to this criticism is the high incidence of major complications, particularly spinal cord compression, which was seen in those in whom treatment was deferred. It is argued that this could have been prevented by close follow up and earlier institution of the deferred hormonal treatment. However, of the 23 patients in whom spinal cord compression occurred in the deferred treatment arm, 19 had already started hormone treatment for some other reason, at times varying from three months to three years before the recorded date of the spinal cord compression.
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The position is less clear cut in those who sustained pathological fractures, and in about half of those developing ureteric obstruction, it did occur before treatment. However, suggesting that the incidence of spinal cord compression could have been reduced by more timely introduction of hormone treatment is not a valid proposition.
Deferred treatment and tumour load
It is an implied justi®cation for deferring treatment that when treatment is started, it will bring the patient's disease back to the point at which it would have been if it had been treated immediately. However, progression of the disease during the period it is untreated must in¯u-ence the effect of hormonal treatment, and the greater disease bulk will have an adverse effect, this probably also explains the reason for the higher incidence of non skeletal soft tissue metastases recorded in deferred treatment (Table 1) .
Applying the study results in practice
For whatever reason, deferring treatment has potential hazards and the onus on the clinician is to justify withholding immediate treatment. The author has a policy of discussing management issues with the patient, and even after introducing the results of the MRC study into such conversations, some men are still reluctant to start treatment when they have no appreciable symptoms. In such cases, my practice is to advise regular monitoring of PSA. If this suggests there is rapid tumour progression, treatment is then started. Otherwise, accepting that a stable PSA is not entirely reliable, 12 careful follow up is mandatory. It is essential if treatment is deferred that the patient and his GP are fully aware of the situation. As regards wider clinical practice, it is the author's impression that the climate was already swinging away from deferred treatment and that the results of the MRC study will be taken as con®rmation of this.
MRC study and the management of prostate cancer Do these results have wider implications? It must be emphasised that the study was restricted to patients with advanced disease. A survival bene®t was only clearly seen in the patients with M0 disease. However, it is not valid to extrapolate from this to justify a policy of adjuvant hormone treatment at even earlier stages of the disease. It does raise this as a tantalising possibility, the urological equivalent of tamoxifen in breast cancer, but just as the VACURG studies made deferred treatment a question in need of answer, so does the MRC study indicate the need for further trials in earlier disease.
Further questions do need asking about the management of locally advanced disease. Immediate hormone treatment appears to have a clear effect on survival, and also gives good local disease control as measured by the reduction in TURP rates. In the past, it has been asked whether adjuvant hormonal therapy in locally advanced disease confers any bene®t to patients receiving radiotherapy. 13 Perhaps the question is now whether the radio-therapy adds any bene®t to hormone therapy, or whether hormone therapy alone is appropriateÐa number of possible trials spring to mind here. Finally it is pertinent to consider the current debates about screening and early diagnosis. It has been possible to take a nihilistic view of prostate cancer. Whether radical surgery or radiotherapy bene®t patients with early disease remains central to this debate. However, in any screening exercise many patients will be detected in whom disease is advanced beyond possible curative treatment. When there was no clear evidence that immediate treatment would affect outcome, there seemed little real bene®t to the patient in earlier diagnosis. It could be argued that in such circumstances, ®nding an incurable tumour sooner merely increased the time for which the patient knows he has cancer without bene®ting him. Indeed this would be an additional argument against screening. On the other hand, if early hormone treatment is bene®cial, and particularly if it mainly bene®ts (in terms of survival) those who have not developed metastatic disease, early detection of even advanced prostate cancer is useful. The MRC study results suggest that treating patients with prostate cancer improves their survival. If this is true, it not only affects how we treat our current patients; it adds another dimension to the debate about prostate cancer screening.
